O-3-Deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-D-streptamine Pentaacetate Salt; Gentamicin D Acetate; Gentamycin C1a Acetate; Gentamicin C3 Acetate

Gentamicin C1a pentaacetate is a prodrug that is converted to gentamicin, its active form, by the enzyme diacetyl reductase. Gentamicin C1a pentaacetate has minimal toxicity and can be used for the treatment of infections caused by gram-positive species. This drug has been shown to be effective against bowel disease and infectious diseases. Gentamicin C1a pentaacetate is enzymatically inactivated by the wild-type strain of Escherichia coli and other gram-negative bacteria. The matrix effect may affect the pharmacokinetics of this drug, which can be studied using an analytical method.